Skip to main content
International Orthopaedics logoLink to International Orthopaedics
. 2005 Jan 13;29(1):30–34. doi: 10.1007/s00264-004-0613-7

Giant cell tumors of the knee: subchondral bone integrity affects the outcome

Tain-Hsiung Chen 1,2,, Yu-Ping Su 2,1, Wei-Ming Chen 2,1
PMCID: PMC3456951  PMID: 15647917

Abstract

From January 1992 to July 2001, we treated 38 patients with giant cell tumour in the knee region. Seventeen tumours were located in the distal femur and 21 in the proximal tibia .Twenty patients were classified as Campanacci grade II, 15 as grade III, and three as grade I. Patients’ mean age was 34.5 (19–65) years, and the mean follow-up was 52 (24–134) months. Operative procedures were chosen according to the extent of bone and soft-tissue involvement. In 28 patients, intralesional curettage and bone grafting was performed and in ten patients a wide resection. We defined subchondral bone of the knee to be affected when the distance to the tumour was less than 3 mm. We then measured the area of affected subchondral bone radiographically using plain radiographs, CT, and MRI. In patients initially treated with curettage and bone grafting, the mean area of initially affected subchondral bone was 18.6 (0–81)%. The mean Enneking functional score at follow-up was 88 (66.6–100). There was a linear trend showing that the larger the area of affected subchondral bone, the worse the functional score. Among patients initially treated with wide resection, the mean area of affected subchondral bone was 68.2 (41–100)%. There was, however, no significant association between affected subchondral bone area and functional score.

Full Text

The Full Text of this article is available as a PDF (117.7 KB).

References

  • 1.Campanacci M, Baldini N, Boriani S, Sudanese A. Giant cell tumor of bone. J Bone Joint Surg Am. 1987;69:106–114. [PubMed] [Google Scholar]
  • 2.Dreinhöfer KE, Rydholm A, Bauer HC, Kreicbergs A. Giant-cell tumours with fracture at diagnosis. Curettage and acrylic cementing in ten cases. J Bone Joint Surg Br. 1995;77:189–193. [PubMed] [Google Scholar]
  • 3.Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Ortop. 1993;286:241–246. [PubMed] [Google Scholar]
  • 4.Fong YC, Chen TH, Chen WM, Lo WH. Giant-cell tumor of bone around the knee. Zhonghua Yixue Zazhi (Taipei) 1997;59:240–247. [PubMed] [Google Scholar]
  • 5.Gamberi G, Serra M, Ragazzini P, et al. Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol Rep. 2003;10:351–356. [PubMed] [Google Scholar]
  • 6.Gitelis S, Mallin BA, Piasecki P, Turner F. Intralesional excision compared with en bloc resection for giant-cell tumors of bone. J Bone Joint Surg Am. 1993;75:1648–1655. doi: 10.2106/00004623-199311000-00009. [DOI] [PubMed] [Google Scholar]
  • 7.Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am. 1970;52:619–664. [PubMed] [Google Scholar]
  • 8.Kauzman A, Li SQ, Bradley G, et al. Cyclin alterations in giant cell tumor of bone. Mod Path. 2003;16(3):210–218. doi: 10.1097/01.MP.0000057235.65327.40. [DOI] [PubMed] [Google Scholar]
  • 9.Kreicbergs A, Lonnquist PA, Nilsson B. Curettage of benign lesions of bone. Factors related to recurrence. Int Orthop. 1985;8:287–294. doi: 10.1007/BF00266874. [DOI] [PubMed] [Google Scholar]
  • 10.Kumta SM, Huang L, Cheng YY, et al. Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 2003;73:1427–1436. doi: 10.1016/s0024-3205(03)00434-x. [DOI] [PubMed] [Google Scholar]
  • 11.Lausten GS, Jensen PK, Schiodt T, Lund B. Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. Int Orthop. 1996;20:172–176. doi: 10.1007/s002640050057. [DOI] [PubMed] [Google Scholar]
  • 12.McDonald DJ, Sim FH, Mcleod RA, Dahlin DC. Giant-cell tumor of bone. J Bone Joint Surg Am. 1986;68:235–242. [PubMed] [Google Scholar]
  • 13.Milz S, Putz R. Quantitative morphology of the subchondral plate of the tibial plateau. J Anat. 1994;185(Pt 1):103–110. [PMC free article] [PubMed] [Google Scholar]
  • 14.Persson BM, Wouters HW. Curettage and acrylic cementation in surgery of giant cell tumors of bone. Clin Orthop. 1976;120:125–133. [PubMed] [Google Scholar]
  • 15.Sanerkin NG. Malignancy, aggressiveness, and recurrence in giant cell tumor of bone. Cancer. 1980;46:1641–1649. doi: 10.1002/1097-0142(19801001)46:7<1641::aid-cncr2820460725>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  • 16.Su YP, Chen WM, Chen TH. Giant-cell tumors of bone: an analysis of 87 cases. Int Orthop. 2004;28:239–243. doi: 10.1007/s00264-004-0564-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Sung HW, Kuo DP, Shu WP, et al. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982;64:755–761. [PubMed] [Google Scholar]
  • 18.Unni KK. Dahlin’s bone tumors: general aspect and data on 11,087 cases. 5. Philadelphia: Lippincott-Raven; 1998. [Google Scholar]
  • 19.Ward WG, Li G., III Customized treatment algorithm for giant cell tumor of bone: report of a series. Clin Orthop. 2002;397:259–270. doi: 10.1097/00003086-200204000-00030. [DOI] [PubMed] [Google Scholar]

Articles from International Orthopaedics are provided here courtesy of Springer-Verlag

RESOURCES